Kiora Pharmaceuticals Inc. (KPRX)
NASDAQ: KPRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KPRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.19M
- EPS (TTM)
- -$2.72
- Dividend yield
- None
- 52-week range
- 0.72 – 2.91
- Day range
- 0.7202 – 0.8155
- Volume / Avg
- 64.69K / 35.23K
- Beta
- —
- Shares outstanding
- 4.42M
52-week range
KPRX stock today
Shares of Kiora Pharmaceuticals (KPRX) finished lower on Nov 20 at $0.7202, a drop of 12.28% or $0.1008 per share, versus the S&P 500's 3.70% decline. Shares are 75.3% below their 52-week high of $2.91, set on Apr 8, 2026 and 0.0% above the 52-week low of $0.72, near the bottom of the past year's range. KPRX is down 63.4% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 61.5%.
Kiora Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$2.72), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kiora Pharmaceuticals
Company profileKiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, which is in phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; and KIO-101, an eye drop formulation for the treatment of ocular presentation of rheumatoid arthritis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Brian M. Strem Ph.D.
- Headquarters
- Encinitas, CA
- Employees
- 13
- Website
- kiorapharma.com
Financial highlights
Full financialsIn fiscal 2025, Kiora Pharmaceuticals generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2021. Kiora Pharmaceuticals reported a net loss of $10.8 million, compared with net income of $3.6 million a year earlier. Diluted earnings per share came in at -$2.64, down from $0.87.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $16.02M | $0 | — | $0 |
| Growth | -100.00% | — | — | — | -100.00% |
| Net income | $-10.84M | $3.59M | $-12.51M | $-13.58M | $-13.77M |
| EPS (diluted) | $-2.64 | $0.87 | $-24.25 | $-18.55 | $-57.12 |
Analyst forecast
ForecastConsensus (1 analysts)
none
Avg. price target
$12.00+1566.20%
- Strong buy 1
- Buy 0
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.28 vs —
KPRX news
All KPRX newsKiora Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NRSNNeuroSense Therapeutics Ltd. | 1.28 | +1.59% | $3.19M | vs KPRX |
| MDCXMedicus Pharma Ltd. | 1.14 | -2.16% | $3.16M | vs KPRX |
| AZTRAzitra Inc | 0.5168 | -2.75% | $3.13M | vs KPRX |
| APREAprea Therapeutics Inc. | 0.229 | -53.56% | $3.25M | vs KPRX |
| GELSGelteq Limited | 0.2701 | -3.74% | $3.11M | vs KPRX |
| SKYESkye Bioscience Inc. | 0.70 | -11.03% | $3.10M | vs KPRX |
| XBIOXenetic Biosciences Inc. | 1.40 | -9.09% | $3.28M | vs KPRX |
| JAGXJaguar Health Inc. | 0.227 | -30.58% | $3.03M | vs KPRX |
Indexes, lists and sector
Kiora Pharmaceuticals stock FAQ
What is Kiora Pharmaceuticals's stock price today?
KPRX last traded at $0.7202 as of Nov 20, 4:00 PM EST, down 12.28% on the day. Prices are delayed at least 15 minutes.
Does Kiora Pharmaceuticals pay a dividend?
No. Kiora Pharmaceuticals does not currently pay a regular cash dividend.
Who is Kiora Pharmaceuticals's CEO?
Dr. Brian M. Strem Ph.D. is the chief executive officer of Kiora Pharmaceuticals Inc., which has about 13 employees.
Has KPRX ever split its stock?
Yes. The most recent KPRX stock split was a 1-for-9 split on Jun 11, 2024, one of 3 splits on record.
What is the KPRX 52-week high?
The 52-week high for KPRX is $2.91 and the 52-week low is $0.72. The stock is currently 75.3% below its high.